Yes, Paxlovid is still recommended for people at higher risk of severe COVID-19. The CDC continues to advise clinicians to consider it for patients with mild or moderate COVID-19 who have one or more risk factors for ending up in the hospital. It is FDA-approved for adults and authorized for patients 12 and older who weigh at least 88 pounds.
Who Should Take It
Paxlovid is aimed at people most likely to get seriously ill from COVID-19. The major risk factors include being over 65 (with risk climbing sharply past 75), being unvaccinated or behind on COVID boosters, having multiple chronic medical conditions, and being immunocompromised or on immunosuppressive medications like chemotherapy. Living in a long-term care facility also raises risk.
The key point: Paxlovid’s strongest evidence of benefit is in high-risk individuals. In the original clinical trial of unvaccinated, high-risk adults, it reduced hospitalizations and deaths by about 5.6 percentage points compared to placebo, meaning roughly 1 in 18 treated patients avoided a hospitalization or death. A later trial in lower-risk patients, many of whom were vaccinated, found no significant difference in symptom relief or hospitalizations. Real-world data from a large Canadian study during 2022-2023 confirmed the pattern. The highest-risk patients saw a 2.5% absolute reduction in severe outcomes, while the benefit shrank and lost statistical significance in lower-risk groups.
Does It Help Prevent Long COVID
A large observational study from the RECOVER initiative found that high-risk patients treated with Paxlovid within five days of infection had a 12% lower risk of developing long COVID, translating to about 3 fewer cases per 100 people treated. The protection extended across multiple body systems: fewer cases of cognitive problems, sleep disorders, shortness of breath, joint pain, fatigue, and loss of taste or smell in the months after infection.
This benefit, however, did not extend to low-risk patients. For people without documented risk factors, there was no measurable reduction in long COVID. The study also found no evidence of benefit for pregnant individuals.
Timing Matters
Paxlovid needs to be started within five days of symptom onset to be effective. The standard course is a five-day regimen taken twice daily. Each dose contains two antiviral tablets plus one booster tablet that helps the antiviral stay active in your body longer. For people with moderate kidney impairment, the dose is reduced to one antiviral tablet plus the booster, twice daily for five days.
If you test positive and have risk factors, the clock starts immediately. Waiting too long to get a prescription can push you outside the treatment window.
Drug Interactions Are a Real Concern
The booster component in Paxlovid (ritonavir) interferes with how your liver processes a long list of other medications. Some combinations are outright dangerous. Certain heart rhythm drugs, seizure medications, specific cholesterol-lowering statins, some sedatives, and even the herbal supplement St. John’s Wort are all contraindicated. Other medications may need their dose temporarily reduced or paused for the five-day treatment course.
This is the most common reason people who would otherwise benefit from Paxlovid can’t take it. Before prescribing, your doctor or pharmacist needs a complete list of everything you take, including supplements. For people on complex medication regimens, particularly older adults, this review is essential and can sometimes rule Paxlovid out entirely.
What About Rebound
Paxlovid rebound, where symptoms or a positive test return after finishing the course, gets a lot of attention but is less common and less unique to the drug than many people assume. In clinical trial data, viral rebound occurred in about 8% of people who took Paxlovid, compared to roughly 6% of people who took a placebo. That difference was not statistically significant once the analysis accounted for people who had already responded to treatment by day five.
More importantly, rebound was not associated with hospitalization or death. Among Paxlovid-treated patients who experienced rebound, only 1.3% were hospitalized, compared to 5.7% of placebo patients who rebounded. In other words, even when symptoms returned briefly, the drug still appeared to provide protection against severe illness.
Cost and Access
Now that Paxlovid has transitioned from government-supplied to commercially distributed, cost varies depending on your insurance. Pfizer’s PAXCESS patient support program offers commercially insured patients savings of up to $1,500 per prescription, potentially bringing the out-of-pocket cost to $25 or even $0. A separate assistance program has provided the drug at no cost to patients on Medicare, Medicaid, TRICARE, and those who are uninsured, though the terms and availability of these programs can change, so it’s worth confirming current coverage when you need a prescription.
Paxlovid is dispensed at retail pharmacies with a prescription. Some telehealth services and pharmacy-based testing programs can streamline the process so you can get tested and prescribed within the same visit, helping you start treatment within that critical five-day window.